ArticleDrug design, development and therapy2026
Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in Patients with Platinum-Resistant or Immunotherapy-Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective, Real-World Study.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: For recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC) that has progressed after platinum-based chemotherapy or immunotherapy, treatment options are limited. This real-world study evaluated the effectiveness and safety of anlotinib, alone or combined with PD-1 inhibitors, in patients with platinum-resistant or PD-1 inhibitor-resistant R/M-NPC. Patients and Methods: This retrospective, single-center study included 86 patients with R/M-NPC who received at least one cycle of anlotinib-based therapy between November 2018 and March 2024. Patients were divided into anlotinib monotherapy (n=53) and anlotinib plus PD-1 blockade combination groups (n=33). The primary endpoint was objective response rate (ORR). Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results: The ORR was significantly higher in the combination group than in the monotherapy group (30.30% vs 7.55%, Conclusion: Anlotinib plus PD-1 blockade significantly improved antitumor activity versus monotherapy in platinum- or PD-1 inhibitor-resistant R/M NPC, with acceptable safety. The favorable trends seen in the immunotherapy-pretreated subgroup are preliminary. These findings support the further evaluation of this combination as a promising therapeutic option in this challenging patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.